Dilara Arslan, Roxani Psychogyiou, Lukas Briner, Jacques Donzé
{"title":"[外周动脉疾病:2024 年更新]。","authors":"Dilara Arslan, Roxani Psychogyiou, Lukas Briner, Jacques Donzé","doi":"10.53738/REVMED.2024.20.897.2249","DOIUrl":null,"url":null,"abstract":"<p><p>Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"20 897","pages":"2249-2252"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Peripheral arterial disease: 2024 update].\",\"authors\":\"Dilara Arslan, Roxani Psychogyiou, Lukas Briner, Jacques Donzé\",\"doi\":\"10.53738/REVMED.2024.20.897.2249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.</p>\",\"PeriodicalId\":21286,\"journal\":{\"name\":\"Revue medicale suisse\",\"volume\":\"20 897\",\"pages\":\"2249-2252\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale suisse\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53738/REVMED.2024.20.897.2249\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2024.20.897.2249","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
外周动脉疾病(PAD)是一个重大的公共卫生问题,由于人口老龄化以及糖尿病、高血压和血脂异常等危险因素的增加,其发病率也在不断上升。治疗 PAD 需要采用多学科方法,而初级保健医生在早期筛查中发挥着至关重要的作用。本文汇集了 2024 年的最新数据以及目前治疗该疾病的方法。简而言之,根据欧洲血管外科学会2024年指南的建议,所有有症状的患者都应接受单一抗血小板治疗,所有血管重建后的患者都应至少接受DAPT(双重抗血小板治疗)或DPI(双重通路抑制)治疗。
Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease. In simplified terms, all symptomatic patients should receive single antiplatelet therapy, and all post-revascularization patients should be on at least DAPT (Dual Antiplatelet Therapy) orDPI (Dual Pathway Inhibition), as recommended by the European Society for Vascular Surgery 2024 guidelines.
期刊介绍:
Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.